Cargando…

L-Dopa response to Cortical Dysfunctions, health related quality of life and Fatigue Severity in Idiopathic Parkinson’s disease

OBJECTIVES: To determine (i) levodopa (L-Dopa) responsiveness on cortical functions, health related quality of life and fatigue severity (ii) relationship between cortical functions, health related quality of life and fatigue severity post L-Dopa treatment of patients with idiopathic Parkinson’s Dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gul, Amara, Yousaf, Javed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2018
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115581/ https://www.ncbi.nlm.nih.gov/pubmed/30190772 http://dx.doi.org/10.12669/pjms.344.14753

Ejemplares similares

Frontal-subcortical defects correlate with task switching deficits in Parkinson’s disease
por: Gul, Amara, et al.
Publicado: (2017)

Novel GCH1 variant in Dopa-responsive dystonia and Parkinson's disease
por: Lewthwaite, A.J., et al.
Publicado: (2015)

Pilot study of atomoxetine in patients with Parkinson’s disease and dopa-unresponsive Freezing of Gait
por: Revuelta, Gonzalo J., et al.
Publicado: (2015)

l-Dopa and Brain Serotonin System Dysfunction
por: Stansley, Branden J., et al.
Publicado: (2015)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

Molecular Effects of L-dopa Therapy in Parkinson’s Disease
por: Dorszewska, Jolanta, et al.
Publicado: (2014)

Beyond L-DOPA: hope for Parkinson’s treatment and diagnosis
Publicado: (2017)

L-DOPA
por: Hornykiewicz, Oleh
Publicado: (2017)

Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
por: Stefano, George B., et al.
Publicado: (2012)

L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning
por: Chagraoui, Abdeslam, et al.
Publicado: (2019)

Altered cerebellar connectivity in Parkinson's patients ON and OFF L-DOPA medication
por: Festini, Sara B., et al.
Publicado: (2015)

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease
por: Hoon, Monique, et al.
Publicado: (2017)

Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
por: Baufreton, Jérôme, et al.
Publicado: (2018)

Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
por: Bello, Fabio Del, et al.
Publicado: (2019)

An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice
por: Huh, Eugene, et al.
Publicado: (2019)

L-Dopa and Behavior
por: Kebabian, John
Publicado: (1974)

Predictive timing functions of cortical beta oscillations are impaired in Parkinson's disease and influenced by L-DOPA and deep brain stimulation of the subthalamic nucleus
por: Gulberti, A., et al.
Publicado: (2015)

Readiness Potential in Parkinson's Disease: Effects of L-Dopa Therapy and Brain Transplants
por: Martínez, D. N. Velázquez, et al.
Publicado: (1992)

The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment
por: Managò, Francesca, et al.
Publicado: (2012)

L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson’s Disease
por: Blosser, Joshua A., et al.
Publicado: (2020)

Individual Magnetoencephalography Response Profiles to Short-Duration L-Dopa in Parkinson’s Disease
por: Peña, Edgar, et al.
Publicado: (2021)

Quantitative Determination of L-DOPA in Seeds of Mucuna Pruriens Germplasm by High Performance Thin Layer Chromatography
por: Raina, Archana P., et al.
Publicado: (2011)

Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson’s disease
por: Wiesen, Tom, et al.
Publicado: (2022)

L-Dopa and the Albino Riddle: Content of L-Dopa in the Developing Retina of Pigmented and Albino Mice
por: Roffler-Tarlov, Suzanne, et al.
Publicado: (2013)

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease
por: Comi, Cristoforo, et al.
Publicado: (2017)

L-dopa treatment increases oscillatory power in the motor cortex of Parkinson's disease patients
por: Cao, Chunyan, et al.
Publicado: (2020)

l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
por: Goshima, Yoshio, et al.
Publicado: (2019)

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
por: Lanza, Kathryn, et al.
Publicado: (2021)

Radiation-induced Brain Calcification Leads to L-dopa-resistant Parkinsonism and Cerebellar Ataxia
por: Shimada, Tomoyo, et al.
Publicado: (2022)

Curcumin modulation of L-dopa and rasagiline-induced neuroprotection in rotenone model of Parkinson’s disease
por: El-Shamarka, Marwa El-Sayed, et al.
Publicado: (2023)

Behavioral effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
por: Sano, Hiromi, et al.
Publicado: (2023)

Reliability and Validity of the Persian Version of the Fatigue Severity Scale in Idiopathic Parkinson's Disease Patients
por: Fereshtehnejad, Seyed-Mohammad, et al.
Publicado: (2013)

Dopa Responsive Slow Orthostatic Tremor in Parkinson’s Disease
por: Lee, Suk Yoon, et al.
Publicado: (2011)

Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease
por: Athulya, RT, et al.
Publicado: (2020)

Herbs containing L- Dopa: An update
por: Ramya, Kuber B, et al.
Publicado: (2007)

Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia
por: Fieblinger, Tim, et al.
Publicado: (2014)

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
por: Svenningsson, Per, et al.
Publicado: (2015)

Deep brain stimulation for Parkinson's disease prior to L-dopa treatment: A case report
por: Servello, Domenico, et al.
Publicado: (2016)

Palmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson Model
por: Park, Hye-Yeon, et al.
Publicado: (2016)

Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease
por: Muthuraman, Muthuraman, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g66f0cge0hvsv9ovn7k399u6sn